The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1270 articles
While most people on GLP-1 medications like Wegovy experience dramatic weight loss, 10-15% are non-responders. Emerging research shows these drugs still deliver benefits for liver disease, heart health, and more—independent of the scale. A new study from Dr. Daniel Drucker's lab uncovers why.
A groundbreaking study shows that Ozempic and Wegovy enhance liver health directly, bypassing the need for weight loss. Canadian researchers uncovered semaglutide's action on key liver cells, challenging old assumptions about GLP-1 therapies. This could transform care for metabolic liver diseases like MASH.
The new FDA-approved Wegovy pill is now available at just $149 per month for starter doses via WeightWatchers Med+, making GLP-1 weight loss therapy more affordable. This self-pay pricing beats typical injectable costs, but it's limited to 1.5mg and 4mg doses for the first four months. Discover eligibility, comparisons, and how to get started before the offer ends April 15.
Stanford Medicine scientists have pinpointed BRP, a naturally occurring peptide dubbed 'natural Ozempic' that slashes appetite and body weight in animal studies without common semaglutide side effects like nausea or constipation. Powered by AI, this discovery targets the brain's hypothalamus for precise metabolic control. Could it offer a safer path to obesity treatment?
Why do some people lose remarkable weight on Ozempic while others see minimal results or severe nausea? A new Nature study of nearly 28,000 GLP-1 drug users shows your genes are a key factor. Specific variants in GLP1R and GIPR genes predict both efficacy and side effects, opening doors to personalized prescribing.
With 1 in 8 American adults now taking GLP-1 medications for diabetes or weight loss, pharmacists are key allies in navigating costs, side effects, and long-term success. Experts like Martin Torres, PharmD, emphasize their role in maximizing benefits while minimizing risks. Here are three essential ways they support your GLP-1 experience.
Semaglutide injections like Ozempic have arrived in India at low prices, exciting millions with diabetes and rising obesity. But experts like Dr. Gagandeep Singh caution it's no magic fix—weight returns upon stopping, muscle loss is common, and misuse risks malnutrition. Understand the real story behind these GLP-1 weight loss injections.
US drugmaker Eli Lilly is set to bring orforglipron, a game-changing oral weight-loss pill, to India following successful global trials that included Indian patients. With obesity rates surging, this daily GLP-1 therapy promises easier access than injectables like Mounjaro. Explore the trial data, market insights, and what it means for patients.
Arecor Therapeutics is advancing AT278, the only ultra-concentrated, ultra-rapid-acting insulin optimized for automated insulin delivery systems, addressing key limitations in current therapies. CEO Sarah Howell shares progress on a US Phase 2 trial partnership and oral GLP-1 platform developments. With a strengthened balance sheet, the company eyes major milestones in diabetes and cardiometabolic treatments.
